The Current Ratio as of September 2024 (TTM) for GH Research PLC (GHRS) is 19.60

According to GH Research PLC’s latest financial reports and current stock price. The company's current Current Ratio is 19.60. This represents a change of -15.60% compared to the average of 23.22 of the last 4 quarters.

GH Research PLC (GHRS) Historical Current Ratio (quarterly & annually)

How has GHRS Current Ratio performed in the past?

The mean historical Current Ratio of GH Research PLC over the last ten years is 38.45. The current 19.60 Current Ratio has changed 5.00% with respect to the historical average. Over the past ten years (40 quarters), GHRS's Current Ratio was at its highest in in the September 2021 quarter at 140.46. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

GH Research PLC (GHRS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of GH Research PLC Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GH Research PLC (GHRS) Average Current Ratio

How has GHRS Current Ratio performed in the past?

The current Current Ratio of GH Research PLC (GHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

GH Research PLC (GHRS) Current Ratio vs. Peers

How is GHRS’s Current Ratio compared to its peers?

GH Research PLC’s Current Ratio is greater than Molecular Partners AG (14.58), greater than MediciNova, Inc. (18.24), greater than Anebulo Pharmaceuticals, Inc. (5.32), greater than Champions Oncology, Inc. (0.69), less than Cyteir Therapeutics, Inc. (21.89), greater than Mineralys Therapeutics, Inc. (11.20), less than Eliem Therapeutics, Inc. (60.41), less than Janux Therapeutics, Inc. (57.34), greater than Rezolute, Inc. (11.82), greater than PMV Pharmaceuticals, Inc. (19.22), greater than Pharvaris N.V. (18.45), greater than PepGen Inc. (7.45), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), greater than Werewolf Therapeutics, Inc. (12.13), greater than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67), greater than Arcus Biosciences, Inc. (5.14), less than Cullinan Oncology, Inc. (28.87), less than Annexon, Inc. (21.81), less than Structure Therapeutics Inc. (41.38), greater than Relay Therapeutics, Inc. (15.64),

Build a custom stock screener for GH Research PLC (GHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GH Research PLC using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GH Research PLC (GHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GH Research PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.